NEXGEL Reschedules Shareholder Update Conference Call to April 15th at 4:30 P.M. ET to Provide Update on Celularity Transaction
MWN-AI** Summary
NEXGEL, Inc. (NASDAQ: NXGL), based in Langhorne, Pennsylvania, has announced a rescheduled shareholder update conference call slated for April 15, 2026, at 4:30 P.M. ET. This call is aimed at providing shareholders with an update on the ongoing negotiations related to the company's potential transaction with Celularity, Inc. Notably, NEXGEL clarified that it will not proceed with financing the transaction through its previously announced Securities Purchase Agreement with a certain institutional investor. Instead, the company is negotiating a new agreement with a different group of investors under a revised financing structure.
The decision to reschedule the call reflects NEXGEL's commitment to ensuring investors are kept informed about significant developments concerning this prospective partnership. Additional information regarding the Celularity transaction is expected to be shared during the conference call.
NEXGEL specializes in the development of ultra-gentle, high-water-content hydrogel products across healthcare, beauty, and OTC categories. The company's product lineup includes renowned brands such as SilverSeal®, Hexagels®, Turfguard®, Kenkoderm®, and Silly George®, and it has established strategic manufacturing partnerships with prominent consumer healthcare companies.
The press release also contains forward-looking statements, emphasizing the inherent risks and uncertainties in predicting future performance, including the consummation of the potential acquisition and related investments. Investors are encouraged to review the company's Annual Report on Form 10-K for potential risk factors that may affect the forward-looking statements provided.
For those interested in participating, details for the live call include a toll-free number for U.S. investors and an international number, as well as access to a webcast for broader participation. The update highlights NEXGEL's focus on transparency and engagement with its shareholder base during a pivotal time for the company.
MWN-AI** Analysis
NEXGEL, Inc. (NASDAQ: NXGL) has made headlines once again, with the announcement of the rescheduling of its shareholder update conference call to April 15, 2026. This call is pivotal as it will provide crucial updates regarding the company’s negotiation process concerning a significant transaction with Celularity Inc. The timing of this rescheduled call is particularly interesting given the broader market climate around healthcare investments.
One of the key takeaways from the announcement is the delay in financing under the previously proposed Securities Purchase Agreement with an institutional investor. This indicates the company is realigning its financial strategies, seeking a new investor group to support the Celularity transaction. Investors should approach this development with cautious optimism; while the ongoing negotiations reflect NEXGEL’s commitment to expanding its operations, the uncertainty around finalizing a deal can lead to volatility in the stock price.
The upcoming conference call on April 15 will be instrumental in clarifying the potential impact of the Celularity transaction on NEXGEL’s growth trajectory. Investors should pay close attention to the details regarding the new financing structure and how it aligns with the company's overall strategy, including its manufacturing and product offerings. As NEXGEL continues to innovate in the healthcare sector with its high-water-content hydrogel products, investor confidence can hinge on successful transaction completions and strategic partnerships.
In summary, while NEXGEL presents an interesting investment opportunity within the healthcare domain, potential investors should monitor the developments closely. Given the inherent risks outlined in their forward-looking statements, a prudent approach would be to consider both the short-term volatility surrounding the upcoming call and the long-term potential of NEXGEL’s product portfolio and market positioning. In light of these factors, it may be wise to wait for further clarity from the April 15 conference before making significant investments.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
LANGHORNE, Pa., April 08, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the rescheduling of its shareholder update conference call to April 15, 2026, at 4:30 P.M. ET.
While there is no assurance that the Celularity transaction will close, the Company will not be financing the transaction under its previously announced Securities Purchase Agreement with a certain institutional investor. The Company is in the process of negotiating a new agreement with a different group of investors under a new financing structure. The Company anticipates providing additional details regarding this proposed transaction with Celularity Inc. on April 15th.
Shareholder Update Conference Call Details:
Date: April 15, 2026
Time: 4:30 P.M. ET
Live Call: 1-800-267-6316 (U.S. Toll Free) or 1-203-518-9783 (International)
Webcast: Events and Presentations
About NEXGEL, Inc.
NEXGEL is a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL brands include SilverSeal®, Hexagels®, Turfguard®, Kenkoderm® and Silly George®. Additionally, NEXGEL has strategic contract manufacturing relationships with leading consumer healthcare companies.
Forward-Looking Statement
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “attempt,” “estimate,” “expect,” “intend,” “plan,” “potential,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “lends,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts, including, without limitation, our ability to consummate the potential acquisition and the related additional investment. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see the Company's Annual Report on Form 10-K for the year ended December 31, 2024, including but not limited to the discussion under “Risk Factors” therein, which the Company filed with the SEC and which may be viewed at http://www.sec.gov/.
Investor Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
Nexgel@KCSA.com
FAQ**
How does the potential financing structure, as mentioned in the context of the NEXGEL Inc. Warrant NXGLW, impact the company's efforts to close the transaction with Celularity Inc.?
Can you provide insights on how the rescheduling of the shareholder update conference call might affect investor confidence in NEXGEL Inc Warrant NXGLW?
What specific details regarding the new financing structure related to NEXGEL Inc Warrant NXGLW can shareholders expect during the call on April 15, 2026?
How should shareholders interpret the forward-looking statements related to the Celularity transaction, especially concerning the NEXGEL Inc Warrant NXGLW?
**MWN-AI FAQ is based on asking OpenAI questions about NexGel Inc (NASDAQ: NXGL).
NASDAQ: NXGL
NXGL Trading
14.42% G/L:
$0.595 Last:
377,697 Volume:
$0.53 Open:
